Associations - PALB2 mutation

BIOMARKER:

PALB2 mutation

Entrez ID:

PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	rucaparib Sensitive: C2 – Inclusion Criteria J Clin Oncol - 2 days rucaparib Sensitive : C2 J Clin Oncol - 2d
PALB2 mutation PALB2 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
PALB2 mutation PALB2 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria ABT-888 Sensitive : C2
PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: C2 – Inclusion Criteria talazoparib Sensitive : C2
PALB2 mutation PALB2 mutation	Breast Cancer Breast Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
PALB2 mutation PALB2 mutation	Urothelial Cancer Urothelial Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
PALB2 mutation PALB2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials FOLFIRINOX Sensitive : C3
PALB2 mutation PALB2 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	lenvatinib Resistant: C3 – Early Trials lenvatinib Resistant : C3
PALB2 mutation PALB2 mutation	Pancreatic Cancer Pancreatic Cancer	oxaliplatin Sensitive: C3 – Early Trials oxaliplatin Sensitive : C3
PALB2 mutation PALB2 mutation	Prostate Cancer Prostate Cancer	PARP inhibitor Sensitive: C3 – Early Trials PARP inhibitor Sensitive : C3
PALB2 mutation PALB2 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	cisplatin + gemcitabine Sensitive: C3 – Early Trials cisplatin + gemcitabine Sensitive : C3
PALB2 mutation PALB2 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin + docetaxel Sensitive: D – Preclinical carboplatin + docetaxel Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES